References
1. Kieffer T.J., Habener J.F. The glucagon-like peptides. Endocr Rev. 1999; 20 (6): 876–913. DOI: https://doi.org/10.1210/edrv.20.6.0385
2. D’Alessio D.A., Vahl T.P. Utilizing the GLP-1 signaling system to treat diabetes: sorting through the pharmacologic approaches. Curr Diab Rep. 2005; 5 (5): 346–52. DOI: https://doi.org/10.1007/s11892-005-0092-2
3. Gerstein H.C., Colhoun H.M., Dagenais G.R., et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo controlled trial. Lancet. 2019; 394 (10 193): 121–50. DOI: https://doi.org/10.1016/S-0140-6736(19)31149-3
4. Cordiner R., Fisher M., Drummond R. SUSTAIN-6: cardiovascular safety of a once-weekly GLP-1 receptor agonist. Pract Diabetes. 2016; 33 (8): 266–74. DOI: https://doi.org/10.1002/pdi.2051
5. Marso S.P., Bain S.C., Consoli A., et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016; 375 (19): 1834–77. DOI: https://doi.org/10.1056/NEJMoa1607141
6. Hernandez A.F., Green J.B., Janmohamed S., D’Agostin R.B., Granger C.B., Jones N.P., et al.; Harmony Outcomes Committees and Investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018; 392 (10 157): 1519–29. DOI: https://doi.org/10.1016/S-0140-6736(18)32261-X
7. Scirica B.M., Bhatt D.L., Braunwald E., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013; 369 (14): 1317–42.
8. Verma S. Potential mechanisms of sodium-glucose co-transporter 2 inhibitor-related cardiovascular benefits. Am J Cardiol. 2019; 124 (suppl 1): 36–44. DOI: https://doi.org/10.1016/j.amjcard.2019.10.028
9. Verma S., Juni P., Mazer C.D. Pump, pipes, and filter: do SGLT2 inhibitors cover it all? Lancet. 2019; 393: 3–5. DOI: https://doi.org/10.1016/S-0140-6736(18)32824-1
10. Santos-Ferreira D., Goncalves-Teixeira P., Fontes-Carvalho R. SGLT-2 inhibitors in heart failure and type-2 diabetes: hitting two birds with one stone? Cardiology. 2020; 145: 311–20. DOI: https://doi.org/10.1159/000504694
11. Neal B., Perkovic V., Mahaffey K.W., de Zeeuw D., Fulcher G., Erondu N., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017; 377: 644–57. DOI: https://doi.org/10.1056/NEJMoa1611925
12. Wiviott S.D., Raz I., Bonaca M.P., Mosenzon O., Kato E.T., Cahn A., et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380: 347–57. DOI: https://doi.org/10.1056/NEJMoa1812389
13. Zinman B., Wanner C., Lachin J.M., Fitchett D., Bluhmki E., Hantel S., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373: 2117–28. DOI: https://doi.org/10.1056/NEJMoa1504720
14. ElSayed N.A., Aleppo G., Aroda V.R., et al.; American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes-2023. Diabetes Care. 2023; 46 (suppl 1): S 140–57.
15. Zelniker T.A., Wiviott S.D., Raz I., Im K., Goodrich E.L., Furtado R.H.M., et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019; 139: 2022–31. DOI: https://doi.org/10.1161/CIRCULATIONAHA.118.038868
16. Figtree G.A., Radholm K., Barrett T.D., Perkovic V., Mahaffey K.W., de Zeeuw D., et al. Effects of canagliflozin on heart failure outcomes associated with preserved and reduced ejection fraction in type 2 diabetes mellitus. Circulation. 2019; 139: 2591–3. DOI: https://doi.org/10.1161/CIRCULATIONAHA.119.040057
17. Antsiferov M.B., Demidov N.A., Balberova M.A., Lobanova O.V., Mudrikova I.G., Gusenbekova D.G. Influence of type 2 sodium-glucose co-transporter inhibitors (dapagliflozin) on the indicators of total mortality in patients with type 2 diabetes (CARDIA-MOS study, Moscow). Sakharniy diabet [Diabetes Mellitus]. 2022; 25 (5): 439–48. DOI: https://doi.org/10.14341/DM12929 (in Russian)